Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine
Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the
most severe cases and when left untreated, leads to death within the first two years of life …
most severe cases and when left untreated, leads to death within the first two years of life …
Antisense oligonucleotide therapies for neurodegenerative diseases
Antisense oligonucleotides represent a novel therapeutic platform for the discovery of
medicines that have the potential to treat most neurodegenerative diseases. Antisense …
medicines that have the potential to treat most neurodegenerative diseases. Antisense …
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study
Abstract Introduction/Aims NURTURE (NCT02386553) is an open‐label study of nusinersen
in children (two SMN2 copies, n= 15; three SMN2 copies, n= 10) who initiated treatment in …
in children (two SMN2 copies, n= 15; three SMN2 copies, n= 10) who initiated treatment in …
Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next
Twenty-five years ago, the underlying genetic cause for one of the most common and
devastating inherited diseases in humans, spinal muscular atrophy (SMA), was identified …
devastating inherited diseases in humans, spinal muscular atrophy (SMA), was identified …
Spinal muscular atrophy—insights and challenges in the treatment era
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by
deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical …
deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical …
Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor
Physiological regulation of transgene expression is a major challenge in gene therapy.
Onasemnogene abeparvovec (®) is an approved adeno-associated virus (AAV) vector gene …
Onasemnogene abeparvovec (®) is an approved adeno-associated virus (AAV) vector gene …
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
Background There is an increasing number of papers reporting the real world use of
Nusinersen in different cohorts of SMA patients. Main body The aim of this paper was to …
Nusinersen in different cohorts of SMA patients. Main body The aim of this paper was to …
Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives
Recent advances in the treatment of spinal muscular atrophy (SMA) have dramatically
altered prognosis. Rather than a rapidly lethal disease, SMA type 1, the most severe form …
altered prognosis. Rather than a rapidly lethal disease, SMA type 1, the most severe form …
[HTML][HTML] Mid-and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec …
Objectives This systematic review aimed to assess mid-and long-term (at least 12 months)
real-world study data from all types of spinal muscular atrophy (SMA) patients treated with …
real-world study data from all types of spinal muscular atrophy (SMA) patients treated with …
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
L Maggi, L Bello, S Bonanno, A Govoni… - Journal of Neurology …, 2020 - jnnp.bmj.com
Objective To retrospectively investigate safety and efficacy of nusinersen in a large cohort of
adult Italian patients with spinal muscular atrophy (SMA). Methods Inclusion criteria were:(1) …
adult Italian patients with spinal muscular atrophy (SMA). Methods Inclusion criteria were:(1) …